Skip to main content

Are Antidepressants Ineffective for the Treatment of Depression in Dementia?


Depression is the most common mood disorder in elderly individuals with Alzheimer disease, with prevalence rates somewhere between 15% to 57%. One major difficulty in dealing with this issue is the inherent difficulty in diagnosing depression in dementia, as evident in the huge prevalence range that I just cited. The other difficulty is figuring out how to treat it.

Antidepressants so far have only showed mixed results in the few studies that have examined their efficacy in Alzheimers. Unfortunately, most of these studies have been either too small or too poor of quality to give much guidance. The Health Technology Assessment Study of the Use of Antidepressants for Depression in Dementia (HTA-SADD) significantly changes this landscape. This multicenter, double-blind, placebo-controlled trial is the largest study to date on this subject. The conclusions do not bode well for antidepressants, although they shouldn't take them off the table as treatment options.

Before we get to the actual results, let's deconstruct the study a little bit. The investigators took 326 elderly patients with dementia (mean age of 79 years; 68% women) from 9 centers providing old-age psychiatry services in England. All participants were diagnosed with comorbid depression for 4 or more weeks and had a score of 8 or more on the Cornell scale for depression in dementia (CSDD). For those who are unfamiliar with the CSDD, it includes both interviews with a caregiver and the patient on 5 domains: mood-related signs, behavioral disturbances, physical signs, cyclic functions (variations in mood & sleep changes), and ideational disturbances.

Participants in the study mostly had moderately severe Alzheimer’s disease with average mini-mental state examination (MMSE) scores of 18, and most were still living in the community (85%). The depression was significant in this population, with mean baseline CSDD scores of 18 and most (68%) having been diagnosed with depression for more than 6 months (a future argument against regression to the mean as we get into the results section).

Individuals were randomly assigned to receive target doses of 150 mg of sertraline (n = 107), 45 mg of mirtazapine (n = 108), or placebo (n = 111) daily. Results showed basically no difference in efficacy between antidepressants and placebo. The CSDD scores decreased for all groups from baseline to week 13 (3.9 for sertraline, 5.0 for mirtazapine, and 5.6 for placebo) with no significant differences between any groups. At 39 weeks, the results showed the same thing, with no real difference between the decreased CSDD scores in all of the groups (4.0 for sertraline, 4.0 for mirtazapine, and 4.8 for placebo). Furthermore, subgroup analysis examining outcomes by baseline depression severity also did not show any significant differences.

Even though there was no difference in the primary outcome of reducing depression, there was a significant increase in adverse events in those taking antidepressants than in those taking placebo (p=0.003). The most common adverse events in those taking sertraline were gastrointestinal reactions (nausea), and the most common in those taking mirtazapine included drowsiness and sedation

So, the main question after reading this aticle is should we continue to prescribe antidepressants in dementia? Well, maybe. I think the most interesting aspect of this trial is the improvement in CSDD scores in the placebo group despite the fact that most were dealing with depression for many months. It should be kept in mind that all of the groups were being cared for in a psychiatric service center in the UK. All we can really say is that antidepressants didn't seem to add any additional benefit to this level of treatment for trial participants. What did this non-pharmacological treatment look like? I’m not sure after reading this article, but treatment in old-age psychiatric services in the UK is probably not the same as usual care as seen in primary care.

I would pretty much agree with Henry Brodaty in the accompanying editorial. He makes it clear that this study does not “advocate abandonment of antidepressants in people with Alzheimer’s disease and depression” and that “therapeutic trials for individual patients are warranted, although not as first-line treatment unless depression is severe.” The caveat to this though is that many of our older adults with dementia do not have access to the non-pharmacologic treatments for depression which may have resulted in the improvements across all groups.


by: Eric Widera

Comments

Mary said…
From Facebook:

After working in dementia care for over twenty years I believe depression is often under treated in persons with dementia. It is presumed that the crying, sad affect and withdrawal are part of the Alzheimers symptoms. I encourage treatment of depression and have often seen excellent results. Persons who were previously taking antipsychotics were able to stop these when they were on antidepressants, they often also help with appetite stimulation. I am not advocating that antidepressants work for everyone, but I think at least a 3 month trial is beneficial
Janmar Delicana said…
Dear Dr. Widera,
It’s a great pleasure to read your blog. I find your post very informative. Thank you for sharing your thoughts.
As a reader, I consider your writing to be a great example of a quality and globally competitive output.
As a moderator for Physician Nexus (a community for physicians) I would like to share your genuine ideas and knowledge. With this you can gain 1000 physician readers on Nexus.
We would love for you to visit our community. It's free, takes seconds, and is designed for physicians only - completely free of industry bias and commercial interests.
Best,
Janmar Delicana
On behalf of the Physician Nexus Team
www.PhysicianNexus.com

Popular posts from this blog

Practical Advice for the End of Life: A Podcast with BJ Miller

This week we talk with BJ Miller, hospice and palliative care physician, public speaker, and now author with Shoshana Berger of the book "A Beginner's Guide to the End."

As we note on the podcast, BJ is about as close as we get to a celebrity in Hospice and Palliative Care.  His TED Talk "What Really Matters at the End of Life" has been viewed more than 9 million times.  As we discuss on the Podcast, this has changed BJ's life, and he spends most of his working time engaged in public speaking, being the public "face" of the hospice and palliative care movement.

The book he and Berger wrote is filled to the brim with practical advice.  I mean, nuts and bolts practical advice.  Things like:
How to clean out not only your emotional house but your physical house (turns out there are services for that!)Posting about your illness on social media (should you post to Facebook)What is the difference between a funeral home and mortuaryCan I afford to die?  …

Improving Advance Care Planning for Latinos with Cancer: A Podcast with Fischer and Fink

In this week's GeriPal podcast we talk with Stacy Fischer, MD and Regina Fink, RN, PhD, both from the University of Colorado, about a lay health navigator intervention to improve advance care planning with Latinos with advanced cancer.  The issue of lay health navigators raises several issues that we discuss, including:
What is a lay health navigator?What do they do?  How are they trained?What do lay health navigators offer that specialized palliative care doesn't?  Are they replacing us?What makes the health navigator intervention particularly appropriate for Latinos and rural individuals?  For advance care planning? Eric and I had fun singing in French (yes French, not Spanish, listen to the podcast to learn why).
Enjoy! -@AlexSmithMD




You can also find us onYoutube!



Listen to GeriPal Podcasts on:
iTunes Google Play MusicSoundcloudStitcher

Transcript

Eric: Welcome to the GeriPal podcast. This is Eric Widera.

Alex: This is Alex Smith.

Eric: And Alex, I'm really excited about toda…

The Dangers of Fleet Enemas

The dangers of oral sodium phosphate preparations are fairly well known in the medical community. In 2006 the FDA issued it’s first warning that patients taking oral sodium phosphate preparations are at risk for potential for acute kidney injury. Two years later, over-the-counter preparations of these drugs were voluntarily withdrawn by the manufacturers.  Those agents still available by prescription were given black box warnings mainly due to acute phosphate nephropathy that can result in renal failure, especially in older adults. Despite all this talk of oral preparations, little was mentioned about a sodium phosphate preparation that is still available over-the-counter – the Fleet enema.

Why Oral Sodium Phosphate Preparations Are Dangerous 

Before we go into the risks of Fleet enemas, lets spend just a couple sentences on why oral sodium phosphate preparations carry significant risks. First, oral sodium phosphate preparations can cause significant fluid shifts within the colon …